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Fetal growth restriction (FGR) is the major single cause of stillbirth1 and is also associated with 
neonatal morbidity and mortality2,3, impaired health and educational achievement in childhood4,5 
and with a range of diseases in later life6. Effective screening and intervention for FGR is an unmet 
clinical need. Here, we performed UPLC-MS/MS metabolomics on maternal serum at 12, 20, and 28 
weeks of gestational age (wkGA) using 175 cases of term FGR and 299 controls from the POP study, 
conducted in Cambridge, UK, to identify predictive metabolites. Internal validation using 36 wkGA 
samples demonstrated that a ratio of the products of the relative concentrations of two positively 
associated metabolites (1-(1-enyl-stearoyl)-2-oleoyl-GPC and 1,5-anhydroglucitol) to the product of 
the relative concentrations of two negatively associated metabolites (5-androstan-3,17-diol 
disulfate and N1,N12-diacetylspermine) predicted FGR at term. The ratio had approximately double 
the discrimination as compared to a previously developed angiogenic biomarker7, the sFLT1:PlGF 
ratio (AUC 0.78 versus 0.64, P=0.0001). We validated the predictive performance of the metabolite 
ratio in two sub-samples of a demographically dissimilar cohort, Born in Bradford, conducted in 
Bradford, UK (P=0.0002). Screening and intervention using this metabolite ratio in conjunction with 
ultrasonic imaging at around 36 wkGA could plausibly prevent adverse events through enhanced 
fetal monitoring and targeted induction of labor. 
 
A large proportion of adverse events associated with FGR are unrelated to maternal risk factors8 and 
this has motivated research on screening for FGR. However, given that the primary intervention for 
FGR is early delivery, screening and intervention could cause harm by iatrogenic prematurity in false 
positives9. This may explain why the most promising approach to screening for FGR, namely, 
universal ultrasound, does not result in better outcomes10. Consequently, the primary method of 
screening for FGR in low risk women in the USA, UK and many other countries remains clinical 
examination, such as measurement of the symphyseal-fundal height11. We have previously argued 
that one approach to the current impasse is to focus initial efforts on screening and intervention at 




have an eight fold increased risk of antepartum stillbirth3. Moreover, early term delivery, while not 
completely benign13, has less potential for harm than preterm delivery4. However, ultrasound is less 
effective as a screening test for term FGR than preterm FGR7,14.  
 
We performed untargeted metabolomics in maternal serum to identify metabolites for use in 
screening tests for term FGR using 175 cases and a random sample of 299 women from the 
Pregnancy Outcome Prediction study (Supplementary Table 1 and Extended Data Fig. 1). Term FGR 
was defined as birth weight <3rd percentile or birth weight 3rd to <10th percentile combined with the 
lowest decile of fetal abdominal growth velocity15,16. The case-cohort study design employed 
combines the advantages of a cohort study with the efficiency of a case control study17. Longitudinal 
mixed effects regression of the log transformed multiple of the median (MoM) for each metabolite 
(see Methods) in the 12, 20 and 28wkGA samples generated a composite P value at 20/28wkGA for 
each metabolite and the P value distribution was skewed towards lower values (Kolmogorov-
Smirnov test P=0.002, Extended Data Fig. 2).  The 100 metabolites with the lowest P values were 
evaluated further. Internal validation was accepted if the P value at 36wkGA was below the 
Bonferroni-corrected P value of 5×10−4: 22 were validated using this highly conservative threshold 
(Supplementary Table 2). A correlation matrix (Supplementary Table 3) demonstrated that the 
levels of some of these metabolites were correlated with each other, with maternal characteristics 
and with the sFLT1:PlGF ratio, an angiogenic biomarker ratio that we have previously shown is 
predictive for FGR7. As the aim of the study was to generate novel predictors, we included the 
sFLT1:PlGF ratio, maternal age, body mass index (BMI) as well as the 22 validated metabolites in a 
forward stepwise logistic regression. Nine of the 22 metabolites were independently predictive of 
FGR and five of these improved the prediction over the sFLT1:PlGF ratio based on area under the 
ROC curve, estimated using 1000-fold bootstrapping to account for over-fitting. One of the five, the 
tobacco metabolite cotinine N-oxide, was excluded from further analyses since smoking is well 





The associations between the four remaining metabolites at 36wkGA and term FGR are shown in 
Table 1. The two metabolites which were positively associated with the risk of term FGR (1-(1-enyl-
stearoyl)-2-oleoyl-GPC (P-18:0/18:1) and 1,5-anhydroglucitol) had a declining trend throughout 
pregnancy (Figs. 1a and 1b).  By contrast, the two metabolites which were negatively associated 
with term FGR (5-androstan-3,17-diol disulfate and N1,N12-diacetylspermine) had an increasing 
trend throughout pregnancy (Figs. 1c and 1d). Hence, each of the four associations observed with 
FGR represented attenuation of the physiological change observed in normal pregnancy.  
 
In order to assess the predictive ability of measurements of the four metabolites in combination, we 
calculated a ratio of the product of the MoMs of the two positively associated metabolites over the 
product of the MoMs of the two negatively associated metabolites (Table 1). We considered the 
possibility that this approach, while appealing in its simplicity, might reduce the information which 
could potentially be obtained by including all four measurements in a multivariable statistical model. 
However, the AUC for the ratio was similar to the AUC for the predicted probability derived from a 
multivariable logistic regression model fitted to the four metabolites (0.778 vs 0.783, respectively, 
P=0.59), hence all further analysis employed the metabolite ratio. The AUC for the metabolite ratio 
for term FGR at 36wkGA was 0.78 compared with 0.64 for the sFLT1:PlGF ratio (Fig. 2a).  
 
For external validation, we first analysed 970 fasting plasma samples (20 FGR and 950 controls) 
obtained between 24 and 28wkGA from the Born in Bradford (BiB) cohort where there was 
information on the birthweight percentile (Extended Data Fig. 3). The BiB study did not include a 
36wkGA blood test and the 24-28wkGA sample was the latest available. The two primary exposures 
pre-defined in the analysis plan were the metabolite ratio and 5-androstan-3,17-diol disulfate as 
a sole predictor and we employed a Bonferroni corrected P value threshold of 0.025 (one-sided). 




associations between the two primary exposures and birth weight percentile <3rd as were observed 
in the POP study (using the 28wkGA sample and the same definition of FGR). When we applied the 
same definition of FGR to both studies, the AUC for the metabolite ratio was similar when measured 
at 24-28wkGA from fasting maternal plasma in the BiB study (0.68, 95% CI: 0.55 to 0.81, P=0.0029 
[one-sided], Fig. 2b) as it was when measured at 28wkGA in non-fasting maternal serum from the 
POP study (0.72, 95% CI: 0.67 to 0.77, Fig. 2b). Subsequently, a second sample became available 
from the BiB study, consisting of 41 cases of FGR and a comparison group of 1513 (Extended Data 
Fig. 4). The AUC for the metabolite ratio in the second sample was 0.62 (95% CI 0.54 to 0.71, 
P=0.0018 [one-sided], Fig. 2b). Logistic regression, as per the analysis plan, yielded P values (one-
sided) of 0.01 in the first sample, 0.004 in the second sample and 0.0002 when both samples were 
pooled. Thus, despite the facts that the BiB cohort sub-samples were demographically highly 
dissimilar to the POP study cohort (Supplementary Tables 4 and 5), that the measurement was 
made earlier in pregnancy, and that the sample obtained was different (fasting plasma rather than 
non-fasting serum), the metabolite ratio was validated in two separate sub-samples from the BiB 
cohort. Moreover, the strength of the association with FGR was similar to the POP study samples 
obtained at comparable gestational windows (Fig. 2b). 
 
We next assessed the diagnostic effectiveness of the metabolite ratio, estimated fetal weight (EFW) 
and the sFLT1:PlGF ratio measured at 36wkGA, in relation to FGR at term in the POP study (Table 2). 
EFW and sFLT1:PlGF were classified by previously defined thresholds (<10th percentile and >38, 
respectively11,18) and the metabolite ratio was classified as >85th percentile, as this is the equivalent 
of sFLT1:PlGF >38 at 36wkGA7. The combination of EFW and the metabolite ratio had the highest 
diagnostic odds ratio. We explored a range of cut-points for EFW and metabolite ratio (Extended 
Data Fig. 5). The combination of EFW<20th and metabolite ratio >80th percentile identified ~56% of 
the term FGR cases while giving a false positive rate of ~5%. The positive likelihood ratio (LR+) was 




positive on the basis of one or both of the predictors being present (i.e. either EFW<20th and/or 
metabolite ratio >80th percentile) was, as expected, less predictive of FGR (positive LR 2.5, [2.2 to 
2.9]) and PPV 10.3% [8.2%-12.8%]). However, the absence of both (i.e. EFW≥20th and metabolite 
ratio ≤80th percentile) was highly effective in ruling out the disease with an extremely low negative 
LR (0.07 [0.03-0.15]) and extremely high NPV (99.7% [99.3%-99.9%]). Hence, using the lowest 20% of 
EFW and highest 20% of metabolite ratio, the population could be divided into three groups: one 
(containing 7.3% of women) with a very high risk of FGR (33.1%, both tests positive), one (containing 
33.3% of women) with an intermediate risk of FGR (5.2%, only one test positive), and one 
(containing 59.4% of women) with a very low risk of FGR (0.3%, neither test positive). 
 
When analysed by phenotype of FGR, the metabolite ratio was more strongly predictive than the 
sFLT1:PlGF ratio of FGR without preeclampsia. Conversely, the sFLT1:PlGF ratio was more strongly 
predictive than the metabolite ratio of FGR with preeclampsia (Fig. 2c). The superior performance of 
the metabolite ratio over the sFLT1:PlGF ratio was also observed when FGR was defined on the basis 
of birth weight percentile combined with the presence of ultrasonic features of FGR (Supplementary 
Table 6). The metabolite ratio was similarly predictive when women with different characteristics 
were compared (Fig. 2d). In the BiB sample 1, the one-sided P value for the other main exposure 
(5-androstan-3,17-diol disulfate) was 0.03, i.e. just above the pre-defined, Bonferroni corrected 
threshold of 0.025. However, in the BiB sample 2, the one-sided P value was 0.001. Moreover, the 
analysis plan pre-specified eight secondary exposures and these were also not validated based on 
the Bonferroni corrected threshold of 0.00625 in either BiB sample (Supplementary Tables 7 and 8 
and Extended Data Fig. 6). However, in most cases the direction and magnitude of the association 
was similar to the associations observed in the POP study.  
 
The four metabolites identified are all plausible markers of FGR. However, only one of these, 




analysis of the current dataset, where the focus was on feto-placental sex and the mother’s serum 
metabolome16. Low levels of 1,5-anhydroglucitol have previously been associated with increased 
birth weight in women with diabetes mellitus19. Therefore, it is plausible that higher levels are 
associated with FGR, although understanding the mechanistic basis of this observation will require 
further studies. 5-androstan-3,17-diol disulfate is a steroid metabolite which was first identified 
in the faeces of pregnant women20. In our analyses, it was strongly correlated with estriol-3-sulfate 
which is itself highly correlated with estriol in pregnant women21. This is relevant as, prior to the 
widespread implementation of ultrasound, low levels of estriol were used to identify placental 
insufficiency22,23. Finally, 1-(1-enyl-stearoyl)-2-oleoyl-GPC is a plasmalogen and elevated placental 
levels of a plasmalogen derivative have previously been described in preeclampsia24 but there are no 
previous studies of FGR, to our knowledge. Interestingly, for all four metabolites, the direction of the 
association with FGR was the opposite of the direction of the association with advancing gestational 
age, i.e. if the metabolite increased with advancing pregnancy, low levels were associated with FGR 
and vice versa. This observation suggests that FGR is associated with attenuation of the physiological 
metabolic changes associated with normal pregnancy, and this could reflect placental growth or 
trophoblast function. We speculate that the most likely explanation is dysregulation of normal 
placental metabolism, as placental dysfunction is thought to underlie many cases of FGR25. 
 
In the current study, we used a statistically rigorous approach to biomarker discovery employing 
both internal and external validation. The P value for the ratio at 36wkGA was 1.1x20-21 hence there 
is very strong evidence supporting the association between the metabolite ratio and term FGR 
within the POP study cohort. The evidence supporting the association was further strengthened by 
external validation in the BiB cohort. The samples of women comprising the BiB cohort were ~53% 
Pakistani ethnicity, ~37% lived in an area in the lowest quintile of socioeconomic status, the majority 
of women had previous births and all women were screened for gestational diabetes using a 75g 




very unlikely that the association is due to some unmeasured confounder. The simplest explanation 
for validation in BiB is that the association between the metabolite ratio and FGR is true and it 
reflects underlying biological processes which are common to all humans. We speculate that 
successful identification of this generalizable association in the POP study reflects the strict 
statistical methods used for the selection of variables combined with the simple demographic 
structure of the POP study cohort, which reduces the potential for noise and bias.   
 
The evidence supporting these associations could be strengthened further by additional studies. In 
particular, the BiB study did not have a 36wkGA sample. A key feature of the POP study was the 
availability of a blood sample near term. This timing of blood sampling was purposeful as we had 
previously suggested that testing in late pregnancy is likely to yield the strongest prediction of 
complications at term12. Hence, it would be interesting to know whether the stronger associations 
near term are also observed in other cohorts. The current study also indicated that the combination 
of EFW<20th and metabolite ratio >80th might be optimal for screening near term. The combination 
of both tests positive had a positive LR of 11, >50% sensitivity and a 5% false positive rate. Similarly, 
when both tests were normal, the negative LR was 0.07 and the NPV was 99.7%. Hence, two thirds 
of women were identified as being either at very high risk or very low risk of FGR. However, these 
thresholds were not pre-specified and further validation would be informative. Importantly, 
validation studies will not need to perform serial ultrasound to define FGR using fetal growth 
velocity, as the ratio was strongly associated with FGR when the outcome was simply defined on the 
basis of birth weight <3rd percentile (Fig. 2c, Supplementary Table 9). Finally, the study design was 
focused on identifying novel predictors of term FGR, and the rationale is described above. Although 
we used preterm blood samples in both the initial phase of biomarker discovery and external 
validation, metabolites were selected on the basis of their association with term FGR. The 
metabolite ratio at 28wkGA was only weakly associated with the risk of preterm delivery of an FGR 




pathophysiology of preterm and term FGR are dissimilar26. Further studies could use the same 
methods employed in the present analysis to identify novel predictors for preterm FGR. 
 
One limitation of the present study is that levels of metabolites were assessed using relative 
concentrations rather than absolute units. Further studies could also address quantification of the 
absolute concentration of metabolites and further analysis of inter- and intra-assay variability. 
However, it is also likely that, even if the absolute concentrations had been known, we would have 
expressed metabolites in terms of MoMs, as the use of relative concentrations in pregnancy is 
already commonplace in other screening contexts. For example, in Down syndrome screening 
maternal levels of proteins and hormones are expressed as MoMs adjusted for gestational age and 
maternal characteristics27. Development of local reference ranges has been shown to increase the 
predictive value of the tests28. The use of MoMs is thought to remove site to site variation in levels 
(in essence, batch effects), hence the MoM more closely reflects the biological variation rather than 
technical variation in the processing of samples or the analysis platform employed. Similarly, in the 
present study, analysis of metabolites by study and sample specific MoMs may have contributed to 
external validation in the BiB cohort, overcoming differences in population, sample type, gestational 
age and sample processing.  
 
Given the associations, we believe that the metabolite ratio, when combined with ultrasonic 
assessment of fetal weight, has potential as a screening test. Next steps are development of 
quantitative assays, validation of diagnostic effectiveness in further populations, and further 
assessment of how the metabolites can be used in combination with other biomarkers, such as 
sFLT1 and PlGF. We found (Fig. 2c) that the metabolite ratio was much more strongly associated 
with FGR in the absence of preeclampsia than the sFLT1:PlGF ratio and the converse was also 
observed. Consequently, when we repeated the analysis and employed a definition of FGR which 




when combined with ultrasound (LR+ 15 to 20) (Supplementary Table 10). Considering the 
complementary nature of the two ratios, combining proteins and metabolites into a single ratio may 
be considered but is beyond the scope of the present study.  
 
Confirmation of the generalizable diagnostic effectiveness of the metabolite ratio would provide a 
rationale for trials of screening and intervention. Screening using the metabolite ratio could take 
different forms. It could be used to select women for ultrasound or, alternatively, both scan and the 
metabolite ratio could be assessed at the same visit. Moreover, the metabolite ratio worked 
similarly irrespective of maternal BMI, hence it could be used to identify women who require further 
assessment if a false negative ultrasound is more likely (e.g. in super obese women). Finally, the ratio 
may be especially useful for screening low risk women. Generally, when diagnostic testing is applied 
to high risk women, the negative predictive value of the test is prioritised as the major concern is 
falsely reassuring women who actually have a problem. However, when screening low risk women, 
the major concern is false positives, as these can lead to medicalisation of healthy women and 
iatrogenic harm. Hence, the potential clinical utility of the metabolite ratio is underlined by the fact 
that the combination of ultrasound and the ratio yielded high positive LRs when both tests were 






Any methods, additional references, Nature Research reporting summaries, source data, statements 
of code and data availability and associated accession codes are available at [link to the online 
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Fig. 1. Levels of predictive metabolites at four gestational time points. (a-d) Mean (95% CI) relative 
concentrations of the four selected metabolites in maternal serum across gestation in cases of fetal 
growth restriction (FGR) born at term or non-cases born at term (control) in the Pregnancy Outcome 
Prediction (POP) study: 1-(1-enyl-stearoyl)-2-oleoyl-GPC (a), 1,5-anhydroglucitol (b), 5-androstan-
3,17-diol disulfate (c), and N1,N12-diacetylspermine (d). The numbers of control/case samples 
were 278/171 at 12 wkGA, 284/171 at 20 wkGA, 283/169 at 28 wkGA, and 275/162 at 36 wkGA. 
Metabolites were quantified using area-under-the-curve of primary MS ions and expressed as the 
multiple of the median value for all batches processed on a given day (see Methods).  Term FGR was 
defined as delivery at ≥37 weeks of gestational age with customized birthweight <3rd percentile, or 
<10th percentile with abdominal circumference growth velocity in the lowest decile (see Methods). 
The P values for the interaction between wkGA and FGR from the mixed effects regression models 
are listed in Supplementary Table 2. The P values for the effect of advancing gestational age 
between 12 wkGA and 28 wkGA were <0.0001 for all four metabolites. 
 
Fig. 2. Receiver operating characteristic (ROC) curve analyses for the prediction of fetal growth 
restriction (FGR). (a) The metabolite ratio (solid line) and the sFLT1:PlGF ratio (broken line) at 36 
weeks of gestational age (wkGA) comparing term FGR (n=162) and controls (n=275) (area under the 
ROC curve [AUC] [95% CI] =  0.78 [0.73 to 0.82] and 0.64 [0.58 to 0.69], respectively, DeLong test 
P=0.0001 [two-sided] for the AUC comparison). The diagonal line represents the AUC of 0.5 (= no 
discrimination). (b) The metabolite ratio in fasting maternal plasma at 24-28 wkGA from the Born in 
Bradford (BiB) study samples 1 and 2 (BiB 1 and BIB 2, respectively) in all subsequent FGR cases 
(n=20 and 41 in BIB 1 and BIB 2, respectively) and controls (n=950 and 1513 in BIB 1 and BIB2, 
respectively) (BiB 1 AUC = 0.68 [95% CI: 0.55 to 0.81], P=0.0029 [one-sided]; BiB 2 AUC = 0.62 [0.54 




shown is the metabolite ratio in non-fasting maternal serum at 20, 28 and 36 wkGA from the POP 
study in all subsequent FGR ≥28 wkGA cases (n=141, 136 and 117, respectively) and  controls (n=295, 
294 and 281, respectively) (20 wkGA AUC = 0.64 [95% CI: 0.58 to 0.69], P<0.0001; 28 wkGA AUC = 
0.72 [95% CI: 0.67 to 0.77], P<0.0001; 36wk GA AUC = 0.80 [95% CI: 0.75 to 0.85], P<0.0001). (c,d) 
The metabolite ratio and the sFLT1:PlGF ratio at 36 wkGA in relation to term FGR by phenotype (c), 
and the metabolite ratio at 36 wkGA in relation to term FGR by maternal or fetal characteristics (d). 
In c and d, the total number of FGR cases was 162 and the total number of controls was 275. In c, 
BW<3rd percentile n=110; BW 3rd to <10th percentile + ACGVD1 n=52; preeclampsia n=14; no 
preeclampsia n=148, and the dotted line represents the AUC of 0.5 (= no discrimination). In d, 
weight categories were based on body mass index cut-offs of 25 and 30 kg/m2. Underweight women 
(<18.5 kg/m2, n=9) were included in the normal weight group. The analysis of estimated fetal weight 
(EFW) included 160 cases and 273 controls due to missing values. In c and d, the vertical dashed lines 
represent AUC comparing all cases and controls. In a, c and d, term FGR was defined as delivery at 
≥37 weeks of gestational age with customized birthweight (BW) <3rd percentile, or <10th percentile 
with abdominal circumference growth velocity in the lowest decile (ACGVD1, see Methods). In b, 
FGR was defined as subsequent delivery with birthweight <3rd centile corrected only for GA and fetal 
sex (see Methods and Supplementary Information). The metabolite ratio was calculated using the 
multiple of the median values, as the ratio of the product of 1-(1-enyl-stearoyl)-2-oleoyl-GPC (P-
18:0/18:1) and 1,5-anhydroglucitol (1,5-AG) divided by the product of 5alpha-androstan-





Table 1. Metabolite measurements and their products and ratios at 36 wkGA in relation to FGRa at term. 1 
   Odds ratiod (95% CI) 
Metabolite AUCb (95% CI) Pc Unadjusted Adjustede Fully adjustedf 
      
(A) 1-(1-enyl-stearoyl)-2-oleoyl-GPC (P-18:0/18:1) 0.64 (0.58 to 0.69) 2.3x10-7 1.76 (1.41 to 2.21) 1.68 (1.34 to 2.12) 1.76 (1.38 to 2.23) 
(B) 1,5-anhydroglucitol (1,5-AG) 0.65 (0.60 to 0.71) 8.4x10-7 1.79 (1.40 to 2.27) 1.65 (1.29 to 2.11) 1.62 (1.26 to 2.07) 
(C) 5α-androstan-3,17-diol disulfate 0.69 (0.64 to 0.74) 3.2x10-11 0.51 (0.41 to 0.64) 0.52 (0.42 to 0.65) 0.51 (0.41 to 0.64) 
(D) N1,N12-diacetylspermine 
 
0.66 (0.61 to 0.71) 1.1x10-5 0.63 (0.51 to 0.79) 0.58 (0.45 to 0.74) 0.58 (0.45 to 0.74) 
Numerator of the metabolite ratio (A x B) 0.70 (0.64 to 0.75) 7.9x10-11 2.18 (1.70 to 2.81) 2.02 (1.56 to 2.61) 2.01 (1.55 to 2.61) 
Denominator of the metabolite ratio (C x D) 0.71 (0.66 to 0.76) 7.6x10-12 0.49 (0.39 to 0.62) 0.48 (0.38 to 0.60) 0.47 (0.37 to 0.60) 
Metabolite ratio (A x B) / (C x D) 0.78 (0.73 to 0.82) 1.1x10-21 2.93 (2.25 to 3.80) 2.86 (2.20 to 3.73) 2.82 (2.17 to 3.68) 
      
 2 
The total number of women who had metabolite measurements at 36 wkGA was 437, including 162 cases of FGR and 275 controls born at term. aFGR at 3 
term was defined as delivery at ≥37wkGA with customized birth weight <3rd percentile, or customized birth weight <10th percentile with abdominal 4 
circumference growth velocity in the lowest decile (see Methods). bAUC was based on the metabolites alone. cCalculated from linear regression using the 5 
Wald test, with the null hypothesis that the coefficient = 0. dOdds ratios were given for one standard deviation higher value of the log-transformed 6 
metabolite, product or ratio. eAdjusted for the log-transformed sFlt-1:PlGF ratio at 36wkGA. fAdditionally adjusted for maternal age (linear and quadratic 7 
term) and body mass index at 12wkGA. wkGA, weeks of gestational age; FGR, fetal growth restriction; CI, confidence interval; AUC, area under the ROC 8 
curve. 9 





Table 2. Diagnostic effectiveness of ultrasonic and biochemical screening at 36 wkGA for delivery of an infant with FGRa at term. 11 
             


























































 Ultrasonic EFW <10th 
and sFLT1:PlGF ratio >38 














 Ultrasonic EFW <10th 
and metabolite ratio >85th 















The total number of women in this analysis was 433, including 160 cases of FGR and 273 controls, due to missing values in EFW for two cases and two 13 
controls. aFGR at term was defined as delivery at ≥37wkGA with customised birth weight <3rd percentile, or customised birth weight <10th percentile with 14 
abdominal circumference growth velocity in the lowest decile (see Methods).  bMetabolite ratio is the ratio of two products of metabolites (see Methods). 15 
As the sFLT1:PlGF ratio >38 approximates to the 85th percentile in the whole POP study cohort, we selected the same threshold in this analysis. cDue to the 16 
case-cohort design, the proportion of screen positives was calculated in the random subcohort, i.e. comparator group, in women who had all three 17 
measurements (EFW, sFLT1:PlGF, metabolite ratio) available (n=287 including 14 cases of FGR and 273 non-cases), and PPV and NPV were weighted by the 18 
inverse of the random subcohort sampling fraction. The proportion of screen positives, sensitivity, specificity, PPV and NPV are given in percentages (%). 19 
wkGA, weeks of gestational age; FGR, fetal growth restriction; TP, true positive; FP, false positive; TN, true negative, FN, false negative; Screen+, screen 20 
positive; Comp, comparator group; LR, likelihood ratio; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; DOR, 21 






The approach of the study was as follows: (i) identify candidate metabolite predictors using the 12, 24 
20 and 28wkGA POP study samples, (ii) validate predictors using the 36wkGA POP study sample and 25 
identify those which were predictive of term FGR independently of maternal characteristics and the 26 
sFLT-1:PlGF ratio, (iii) validate the predictors externally using the Born in Bradford (BiB) cohort. 27 
 28 
Study design  29 
The POP study has been described previously in detail29,30. It was a prospective cohort study of 30 
unselected nulliparous women with a singleton pregnancy attending the Rosie Hospital, Cambridge, 31 
UK, between Jan 2008 and Jul 2012. Participants had repeated blood sampling and fetal biometry at 32 
12, 20, 28 and 36wkGA. Outcome data were obtained by linkage to the hospital’s electronic 33 
databases and individual review of paper case records. Ethical approval was obtained from the 34 
Cambridgeshire 2 Research Ethics Committee (reference number 07/H0308/163). All study 35 
participants gave written informed consent. This study is reported according to the STARD 2015 36 
guidelines for reporting diagnostic accuracy studies (http://www.stard-statement.org/). A case-37 
cohort design within the POP study was used for the metabolomics analysis31. FGR at term was 38 
defined as delivery at ≥37wkGA and (a) customized birth weight (BW) centile <3rd or (b) customized32 39 
birth weight (BW) centile <10th combined with abdominal circumference growth velocity (ACGV) in 40 
the lowest decile between 20 and 36 wkGA. A random sample of the cohort was selected as a 41 
comparison group 42 
 43 
External validation: the BiB Cohort 44 
The BiB cohort has been described in detail elsewhere33,34 and was conducted between 2007 and 45 
2011. The cohort members, excluding those with pre-existing diabetes, were invited for a glucose 46 
tolerance test at 24-28wkGA, and 85% of the women had valid test data. 1000 women from the BiB 47 





also had a second sample of 2000 women who underwent metabolic profiling at Metabolon. Whilst 49 
the first BiB sample (n=1000) was random, the second sample selection was designed similarly to 50 
POPs in a case-cohort design, sampled for cases of gestational diabetes, gestational hypertension, 51 
pre-eclampsia, preterm birth and still birth, but not FGR. Therefore, we used the FGR cases and non-52 
cases available in the random sub-cohort (n=1554) from the second BiB sample in the analysis. This 53 
was an independent sample to the first BiB sample and we did not pool the metabolite MoMs from 54 
the two samples due to different normalisation. Both BiB samples are half White British and half 55 
Pakistani origin because these are the main homogeneous ethnic groups in the area.  56 
Ultrasonic measurements of abdominal circumference and fully customized BW centiles were not 57 
available for all women in the BiB cohort. Therefore, a modified definition of FGR was employed in 58 
the BiB cohort: birth weight <3rd centile corrected for GA and fetal sex using the Hadlock 199135 59 
reference range (see Analysis plan below). When we compared data from the POP study and BiB, the 60 
same modified definition of FGR was employed in the POP study to allow a direct comparison 61 
between the two cohorts. P values for external validation were one-sided as validation was 62 
directional, i.e. we would not regard an association as validated if the P value was below the given 63 
threshold but the association was in the opposite direction to that predicted. The analysis plan pre-64 
specific logistic regression as the analytic method to generate the P value. We also performed a post 65 
hoc analysis of the BiB cohort using ROC curve analysis to allow direct comparison of associations 66 
with the POP study. Again, a one-sided P value was reported. 67 
 68 
Biochemical analyses 69 
Measurement of sFLT1 and PlGF protein levels (undertaken only in the POP study) was performed on 70 
maternal serum using the Roche Cobas e411 immunoassay platform, as previously described36. 71 
Metabolomic analysis was performed by Metabolon (Research Triangle Park, NC, USA), blinded to 72 
the patients’ clinical information and pregnancy outcome, as previously described31. In both studies, 73 





used as the analysis platform37. Metabolite concentrations were quantified using area-under-the-75 
curve of primary MS ions and were expressed as the multiple of the median (MoM) value for all 76 
batches processed on the given day. In the POP study, analysis batches contained 36 maternal serum 77 
samples each and all samples from the same woman were included in the same batch (hence 78 
including the full range of gestational ages). Moreover, batches were designed so that the 79 
proportion of samples from cases and controls was the same in all batches. The calculated 80 
metabolite products and ratios were derived from multiplication and division of the MoM values. 81 
1193 untargeted metabolites were measured from each sample, 837 of known structural identity. 82 
Eight xenobiotic metabolites were not analysed as they demonstrated minimal variation. In the POP 83 
study, metabolomics was performed on serial non-fasting serum obtained at around 12, 20, 28 and 84 
36wkGA, whereas BiB samples were plasma samples (ethylenediamine tetraacetic acid tubes) 85 
obtained once from each woman at 24-28wkGA after an overnight fast. The relative standard 86 
deviations (%RSD) for the four metabolites used in the metabolite ratio were: 19.5% for 1‐(1‐enyl‐87 
stearoyl)‐2‐oleoyl‐GPC (P‐18:0/18:1), 10.3% for 1,5‐anhydroglucitol (1,5‐AG), 5.8% for 5alpha-88 
androstan-3alpha,17alpha-diol disulfate and 10.8% for N1,N12-diacetylspermine. These values were 89 
derived from the QC matrix of pooled EDTA plasma or serum. 90 
 91 
Statistical analysis 92 
The calculation of metabolite products and ratios was performed using the metabolite MoMs. 93 
Metabolite MoMs, products and ratios were log-transformed prior to linear regression. Additionally, 94 
in logistic regression, the log transformed values were converted to z scores to allow direct 95 
comparison of the estimated effect sizes. Initial selection of predictive metabolites involved fitting 96 
longitudinal linear mixed models for each metabolite using measurements from 12wkGA, 20wkGA, 97 
and 28wkGA, to generate a difference in the metabolite means and associated P value in the 98 
maternal serum at 20wkGA and/or 28wkGA (composite Chi-squared test) comparing term FGR cases 99 





differences and the metabolites were then ranked by the composite P value at 20/28wkGA. Excess 101 
of low P values was tested using a one-sample Kolmogorov-Smirnov test against the theoretical 102 
uniform distribution of P values between 0 and 1. The 100 metabolites with the lowest P values were 103 
selected for further study. Internal validation used the 36wkGA sample in the same women and 104 
cases and controls were compared using linear regression. Internal validation was accepted if the P 105 
value at 36wkGA was below the Bonferroni-corrected threshold P<5×10−4. Forward-stepwise logistic 106 
regression (P<0.05 for entry and P<0.1 for removal) was used to select independent predictors of 107 
term FGR. In addition to the metabolites internally validated at 36wkGA, the forward-stepwise 108 
logistic regression included the sFlt-1:PlGF ratio at 36wkGA, maternal age (linear and quadratic 109 
terms) and maternal BMI at 12wkGA. The metabolites selected based on the forward-stepwise 110 
logistic regression were further assessed on whether they improved the area under the receiver 111 
operating characteristic (ROC) curve (AUC) in the prediction of term FGR over the sFLT1:PlGF ratio. In 112 
this step, the AUC was estimated using 1000-fold bootstrapping to avoid optimism through 113 
overfitting. The metabolites were added into a logistic regression model for the sFLT1:PlGF ratio, 114 
starting from the most informative metabolite, until the increase in the corrected AUC on adding an 115 
additional metabolite was <0.01. The metabolites from this step were then used to calculate 116 
products and ratios of the unprocessed MoMs generated by Metabolon and AUCs (95%CI) of the 117 
products and ratios were reported. These were not corrected for optimism as they were treated as 118 
single predictors in the analyses and this did not involve fitting coefficients using a multivariable 119 
model. Additionally, unadjusted and adjusted odds ratios (95% CI) were reported for a one standard 120 
deviation higher value of the log-transformed metabolite, product or ratio. Standard screening test 121 
statistics (sensitivity, specificity, positive and negative likelihood ratio, positive and negative 122 
predictive value and diagnostic odds ratio) were calculated from 2x2 tables in the POP study cohort, 123 
weighting the comparison group by the inverse of the sampling fraction where appropriate. A power 124 
calculation for validation of the metabolite ratio was performed using the effect size obtained from 125 





study. External validation in the BiB study was pre-specified in an analysis plan (see below) which 127 
was informed by the power calculation. To account for differences in the two samples from the BiB 128 
study, the pooled statistics (odds ratio and AUC and their 95%CI) were obtained by first taking a z 129 
score of the log-transformed ratio separately in both samples and by calculating the statistics from 130 
the pooled data of sample-specific z scores. Statistical analysis was performed using Stata version 131 
15.1 and R version 3.4.4. 132 
 133 
Analysis plan for external validation of associations between metabolites and FGR in the Born in 134 
Bradford study 135 
Outcome 136 
FGR, defined as birth weight percentile <3rd, applying the 1991 Hadlock formula35 to sex-adjusted 137 
weights (see Methods section below). Births at any gestational age subsequent to the measurement 138 
of the metabolites are included. 139 
Exposures 140 
Scaled imputed metabolite values (multiples of the median) from maternal serum or plasma are 141 
used to calculate the following from the measurements taken at 24-28 weeks of gestation: 142 
The main exposures are:  143 
1. the ratio of two products of metabolites: (1. x 2.) / (3. x 4.), where 144 
1. 1-(1-enyl-stearoyl)-2-oleoyl-GPC (P-18:0/18:1) 145 
2. 1,5-anhydroglucitol (1,5-AG) 146 
3. 5alpha-androstan-3alpha,17alpha-diol disulfate 147 
4. N1,N12-diacetylspermine 148 
2. 5alpha-androstan-3alpha,17alpha-diol disulfate (as sole predictor) 149 
Note: we will accept validation as a Bonferroni corrected threshold for alpha (<0.025), one-sided 150 
(given known directionality of association being tested). 151 





(i) The product of metabolites 3. and 4. above, i.e. the denominator of main exposure 1. 153 
(ii) The product of metabolites 1. and 2. above, i.e. the numerator of main exposure 1. 154 
(iii) Steroid ratio / Polyamine ratio, where  155 
Steroid ratio = 4-androsten-3beta,17beta-diol monosulfate (2) / 5alpha-androstan-156 
3alpha,17alpha-diol disulfate. 157 
Polyamine ratio = N1,N12-diacetylspermine / Acisoga. 158 
(iv) All of the other individual metabolites listed above (metabolites 1., 2., 4.,  4-androsten-159 
3beta,17beta-diol monosulfate (2) and Acisoga) as sole predictors.  160 
Given the number of hypotheses, these will be treated as “hypothesis generating” and accepting an 161 
uncorrected P<0.05 as the metabolite being potentially associated with FGR but requiring further 162 
validation. However, if any of the secondary exposures are P<0.00625 (one-sided, Bonferroni 163 
corrected for 8 comparisons – two products of metabolites, one ratio of ratios and five individual 164 
measures), we would accept this as validation of the POP study results. 165 
Any associations observed in the opposite direction from the POP study will be disregarded, given 166 
the use of one-sided tests. 167 
Transformation of exposures 168 
Log-transform all exposures, e.g. if the main exposure variable 1 is named mainratio,  169 
log10mainratio = log10(mainratio).  170 
Turn the log-transformed ratios into z scores. In the POPs, the mean and SD of log-transformed 171 
ratios for calculating z scores were obtained from the comparator group which is representative of 172 
the whole POPs cohort. In the BiB study, you can use the population mean and SD, 173 
log10mainratioZ = [log10mainratio - mean(log10mainratio)] / SD(log10mainratio). 174 
Statistical analysis 175 
Fit a logistic regression model separately for each exposure and FGR (outcome). Report the odds 176 
ratio, 95%CI and P value (one-sided) from each analysis. Perform a ROC curve analysis and calculate 177 





Methods for calculating gestational age and fetal sex adjusted birth weight percentiles 179 
There were 13524 participants in the BiB dataset with information on birth weight, fetal sex and 180 
gestation length (both in weeks and days and in completed weeks). We adjusted each of these birth 181 
weights for fetal sex, applied the Hadlock 1991 formulas to these sex-adjusted weights and defined 182 
FGR as follows: 183 
1. Participants were grouped by gestation length (in completed weeks). To get adequate 184 
numbers of participants in each group (>50), we combined the weeks 24-28, 29-31, 32-33 185 
and 42-44. All other weeks (34-41) were analysed independently, so that there were 12 186 
groups altogether. 187 
2. Within each group i we calculated the mean birth weights for both males (m[i]) and females 188 
(f[i]), and the difference (d[i]) in the means for each group (d[i]= m[i]- f[i]). 189 
3. We adjusted the birth weights within each group as follows: 190 








where m*[i] and f*[i] are the sex-adjusted birth weights. 191 
4. We applied the 1991 Hadlock formulas to each of the 13524 participants (using gestation 194 
length as weeks and days [in decimal form]). We then calculated z-scores for each 195 
participant using the sex-adjusted birth weights defined above. 196 
5. We defined FGR in the BiB dataset as a z-score (defined above) <3rd percentile of all 197 
participants. 198 
A similar method in the POP study cohort (n=4212) was applied to obtain gestational age and fetal 199 
sex adjusted birth weight percentiles and to define FGR. This definition was used when the results 200 
from the BiB and POP study cohorts were presented together. 201 
 202 





Source data for Figs. and Extended Data Figs. are available online. Since the individual patient data 204 
contain confidential information, it can be supplied only in an anonymised format to suitably 205 
qualified researchers who can make appropriate institutional commitments relating to data security 206 
and confidentiality. Data requests should be addressed to U.S. or G.C.S.S. 207 
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